Available Trials

Memory Improvement Through Nicotine Dosing (MIND) Study

The purpose of this study is to determine whether nicotine (in patch form) improves memory and functioning in adults diagnosed with Mild Cognitive Impairment. This study, which will take place at multiple sites across the U.S., will consist of 12 visits over a 2-year period.

What is MCI?

Mild Cognitive Impairment (MCI) is a state of memory loss that is between normal aging and early Alzheimer’s disease. It may involve problems with memory, language, thinking and judgment that are greater than normal age-related changes. These symptoms of early memory loss are often noticed by the individual, as well as family members or friends. At this point, the cause(s) of MCI is unknown.

Do I have to already be diagnosed with MCI in order to participate?

No, though there must be memory concerns which are noticed by another person. Memory testing will be done at the screening visit to determine eligibility.

Eligibility

Healthy, non-smoking adults, age 55+ who notice changes in their memory or whose family member notice changes, may be eligible to participate. Those who meet the study qualifications will be placed on either daily nicotine or placebo patches.

All study participants need to have a study partner who will accompany them to visits.

There is no cost to participate in this study.

To learn more, contact:

Director of Research Operations

Amy Saklad

210-567-8229

saklada@UTHealthSA.org